


**Patient presents with inflammatory back pain to GP /MSK
 Clinician Refer PMSK Partnership/Rheumatology (external or
 internal)
 Review by rheumatologist within 2-4 weeks Initial medical
 diagnosis of Axial Spondyloarthritis
 (Modified New York criteria/ASAS criteria)**



References

- BMJ Best Practice (2018) *Ankylosing spondylitis*. BMJ Publishing Group Ltd. <http://bestpractice.bmj.com>
- Bohn, R., Cooney, M. and Deodhar, A. (2018) Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature. *Clinical and Experimental Rheumatology* **36**(2), 263-274.
- Braun, J., van den Berg, R., Baraliakos, X., *et al.* (2011) 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Annals of Rheumatic Diseases* **70**(6), 896-904.
- BSR and BHPR (2017) BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. *Rheumatology* **56**(2), 313-316.
- Cooksey, R., Husain, M.J. and Brophy, S. (2015) The cost of ankylosing spondylitis in the UK using linked routine and patient-reported survey data. *PLoS One* **10**(7).
- Cooper, C., Carbone, L., Michet, C.J., *et al.* (1994) Fracture risk in patients with ankylosing spondylitis: a population based study. *Journal of Rheumatology* **21**(10), 1877-1882.
- de Koning, A., Schoones, J.W. and van der Heijde, D. (2018) Pathophysiology of axial spondyloarthritis: consensus and controversies. *European Journal of Clinical Investigation* **48**(5).
- Dean, L.E., Jones, G.T. and MacDonald, A.G. (2014) Global prevalence of ankylosing spondylitis. *Rheumatology* **53**(4), 650-657.
- Fang, W. *et al.*, (2016) The effectiveness of a real life dose reduction strategy for TNFi in ankylosing spondylitis and psoriatic arthritis. *Rheumatology*. 55 1837-1842
- Gratacos, J. (2019) Non-inferiority of dose reduction vs standard dosing of TFNi in axial spondyloarthritis. *Arthritis Research and Therapy*. 21(11) 3-10
- Hamilton, L., Macgregor, A. and Toms, A. (2015) The prevalence of axial spondyloarthritis in the UK: a cross-sectional cohort study. *BMC Musculoskeletal Disorders* **16**, 392Kiltz, U., Baraliakos, X. and Regel, A. (2017) Causes of pain in patients with axial spondyloarthritis. *Clinical and Experimental Rheumatology* **35**(Suppl 107), 102-107. Kim, T.H., Uhm, W.S. and Inman, R.D. (2005) Pathogenesis of ankylosing spondylitis and reactive arthritis. *Current Opinion in Rheumatology* **17**(4), 400-405.
- Kroon, F.P.B., van der Burg, L.R.A. and Ramiro, S. (2015) *Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) (Cochrane Review)*. Issue 2. John Wiley & Sons, Ltd. <http://www.cochranelibrary.com>
- Li, J. *et al.*, (2016) Dose reduction of recombinant human tumor necrosis factor inhibitors (etanercept can be effective in ankylosing spondylitis patients with synovitis of the hip in a Chinese population). *International Journal of Immunopathology and Pharmacology*. 29(3) p510-515
- Maxwell, L.J., Zochling, J. and Boonen, A. (2015) *TNF-alpha inhibitors for ankylosing spondylitis (Cochrane Review)*. Issue 2. John Wiley & Sons, Ltd. <http://www.cochranelibrary.com>
- McAllister, K., Goodson, N. and Warburton, L. (2017) Spondyloarthritis: diagnosis and management: summary of NICE guidance. *BMJ* **356**.
- Millner, J.R., Barron, J.S. and Beinke, K.M. (2016) Exercise for ankylosing spondylitis: an evidence-based consensus statement. *Seminars in Arthritis and Rheumatism* **45**(4), 411-427.
- Mitra, D., Elvins, D.M., Speden, D.J. and Collins, A.J. (2000) The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. *Rheumatology* **39**(1), 85-89.
- NICE (2016) *TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis*. Technology appraisal guidance [TA383]. National Institute for Health and Care Excellence. <http://www.nice.org.uk>
- NICE (2017a) *Spondyloarthritis in over 16s: diagnosis and management*. NICE guideline [NG65]. National Institute for Health and Care Excellence. <http://www.nice.org.uk>
- NICE (2017b) *Spondyloarthritis in over 16s: diagnosis and management (full guideline)*. NICE guideline NG65. Methods, evidence and recommendations. National Institute for Health and Care Excellence. <http://www.nice.org.uk>
- NICE (2018) *Spondyloarthritis (Quality Standard)*. National Institute for Health and Care Excellence. <http://www.nice.org.uk>
- Peters, M.J., van der Horst-Bruinsma, I.E., Dijkmans, B.A. and Nurmohamed, M.T. (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. *Seminars in Arthritis and Rheumatism* **34**(3), 585-592.
- Ralston, S.H., Urquhart, G.D., Brzeski, M. and Sturrock, R.D. (1990) Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. *British Medical Journal* **300**(6724), 563-565.

- Reid, V. et al., (2018) Biologics pathway for ankylosing spondylitis (including non-radiographic axial spondyloarthritis - AS) and psoriatic arthritis PsA. GMMMG NHS. version 4.2 p1-22
- Rohekar, S., Chan, J. and Tse, S.M. (2015) 2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis. Part II: Specific management recommendations. *Journal of Rheumatology* **42**(4), 665-681.
- Rudwaleit, M., van der Heijde, D., Khan, M.A., et al. (2004) How to diagnose axial spondyloarthritis early. *Annals of the Rheumatic Diseases* **63**(5), 535-543.
- Rudwaleit, M., van der Heijde, D., Landewe, R., et al. (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Annals of the Rheumatic Diseases* **68**(6), 777-783.
- Sieper, J. and Poddubnyy, D. (2017) Axial spondyloarthritis. *Lancet* **390**(10089), 73-84.
- Sieper, J. (2012) How to screen for axial spondyloarthritis in primary care? *Current Opinion in Rheumatology* **24**(4), 359-362.
- Smolen, J.S., Schols, M. and Braun, J. (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. *Annals of the Rheumatic Diseases* **77**(1), 3-17.
- Stolwijk, C., van Tubergen, A. and Castillo-Ortiz, J.D. (2015) Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. *Annals of the rheumatic diseases* **74**(1), 65-73.
- Stolwijk, C., van Onna, M. and Boonen, A. (2016) Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. *Arthritis Care and Research* **68**(9), 1320-1331. Taurog, J.D., Chhabra, A. and Colbert, R.A. (2016) Ankylosing spondylitis and axial spondyloarthritis. *New England Journal of Medicine* **374**(26), 2563-2574.
- van der Heijde, D., Ramiro, S. and Landewe, R. (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Annals of the Rheumatic Diseases* **76**(6), 978-991.
- van der Linden, S. and Valkenburg, H.A. and Cats, A. (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis & Rheumatism* **27**(4), 361-368.
- Ward, M.M., Deodhar, A. and Aki, E.A. (2016) American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis and Rheumatology* **68**(2), 282-298.
- Zavada, J. et al., (2016) A tailored approach to reduce dose of anti-TNF drugs may be equally effective but substantially less costly than standard dosing in patient with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. *Annals of Rheumatic Disease*. 75 p96-102

Pennine MSK Partnership - Ankylosing Spondylitis Pathway

Reviewed by: C Burns 15/11/2023

Review Date: 15/5/2025

Expiry: 15/11/2025